The Challenge of Immunotherapy: Staying on Target
Immunotherapies Can Produce Side Effects That Mimic Autoimmune Diseases
Seeking New Users for iSeq
The Changing Sequencing Landscape
Cell Therapy Manufacturing: All Signs Point to Commercialization
As Milestones Are Reached, Best Practices Will Become Less Hazy
Kite Earns Patent for Method to Increase Efficacy of CAR-T
Company Snags Rights for Use of Optimal Preconditioning Regimen
For full access to this article login to GEN Select now.
Membrane Protein Solutions for Antibody Discovery
Generation of Monoclonal Antibodies against Difficult Membrane Protein Targets
- Biologics are the fastest growing class of pharmaceuticals, with hundreds of monoclonal antibodies (mAbs) currently being developed and over thirty mAbs approved for the treatment of conditions ranging from cancer to autoimmune and inflammatory diseases. In the case of membrane protein targets, mAbs can avoid many of the pitfalls ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.